2011
DOI: 10.1038/bjc.2011.222
|View full text |Cite
|
Sign up to set email alerts
|

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target

Abstract: Background:The aim of this study was to investigate the patterns of epidermal growth factor receptor (EGFR) overexpression, EGFR gene amplification, and the presence of activating mutations in the tyrosine kinase domain of this gene in squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas of the uterine cervix.Methods:The EGFR expression, amplification, and mutation in cervical carcinomas were assessed by immunohistochemistry, fluorescence in situ hybridisation, and PCR–SSCP, respectively, and … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
56
0
2

Year Published

2013
2013
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 66 publications
(61 citation statements)
references
References 40 publications
3
56
0
2
Order By: Relevance
“…EGFR is also known as the HER (Human Epidermal factor Receptor) receptor and is a target for treatment. EGFR/HER family inhibitors, such as gefitinib, erlotinib, cetuximab, lapatinib, trastuzumab, panitumumab, are being evaluated in cervical cancer and are reviewed in depth (Lida et al, 2011;Soonthornthum et al, 2013;Vici et al, 2014). Most of these are injectables (subcutaneous, intramuscular or intravenous), whilst some like erlotinib, are available as oral tablets.…”
Section: Egfrmentioning
confidence: 99%
“…EGFR is also known as the HER (Human Epidermal factor Receptor) receptor and is a target for treatment. EGFR/HER family inhibitors, such as gefitinib, erlotinib, cetuximab, lapatinib, trastuzumab, panitumumab, are being evaluated in cervical cancer and are reviewed in depth (Lida et al, 2011;Soonthornthum et al, 2013;Vici et al, 2014). Most of these are injectables (subcutaneous, intramuscular or intravenous), whilst some like erlotinib, are available as oral tablets.…”
Section: Egfrmentioning
confidence: 99%
“…In addition, previous studies identified that the frequencies of NRAS, HRAS and BRAF hotspot mutations were absent or low in cervical squamous cell carcinoma or adenosquamous carcinoma (11,21,25,26). Similarly, the current study also did not identify the potential hotspot mutations in these genes in the 260 cases of cervical carcinoma with distinct subtypes.…”
Section: Discussionmentioning
confidence: 41%
“…Согласно результатам, полученным Li и соавт., увеличение числа копий EGFR-гена может быть причиной примерно трети случаев гиперэкспрессии рецептора при ЦИН2/3 и РШМ [59], следовательно, это не единственный механизм, реализуемый in vivo. Схожие результаты получены и другими авторами [60,61].…”
Section: факторы роста: эпидермальный фактор роста (Egf) и его рецептunclassified